By Carla J. Baumel, Ellen K. Levish, Kai Rüting, and Sarah Taylor
Robins Kaplan attorneys Carla Baumel and Ellen Levish, alongside Pinsent Masons attorneys Kai Rüting and Sarah Taylor, examine the U.S. Supreme Court’s Hikma decision and its implications for pharmaceutical patent strategy. The authors explore how the ruling clarifies the infringement risks associated with “skinny labels” in the U.S., compare evolving approaches in the U.K., Germany, and the Unified Patent Court, and consider what the differing frameworks mean for brand and generic companies developing global patent, launch, and litigation strategies.
Related Attorneys
Counsel
Associate
